FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

Last month, March 2025, the CGTLive^® team was diligently tracking the FDA's activities related to the development of cell and gene therapies for the treatment of rare, complex, and otherwise challenging diseases and disorders.